Zentalis Pharmaceuticals, Inc.(ZNTL)

Biotechnology · San Diego, CA

$2.67-0.11 (-3.96%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:39:17.480Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:39:17.480Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.67
Unrounded diluted TTM EPS · period ending 2026-06-30: -2.46

FMP input reference: e5b22bec38318fdeba07533daebf1876a752163d7d28918210f347f826af404f

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ZNTL PE Ratio Metrics

PE RATIO

N/A

ZNTL Competitors' PE Ratio

ZNTL

Zentalis Pharmaceuticals, Inc.

Current

Market Cap

$190.07M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs ZNTL

Market Cap

$189.11M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RXST

RxSight, Inc.

vs ZNTL

Market Cap

$192.49M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SRZN

Surrozen, Inc.

vs ZNTL

Market Cap

$197.18M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANTX

AN2 Therapeutics, Inc.

vs ZNTL

Market Cap

$182.60M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XGN

Exagen Inc.

vs ZNTL

Market Cap

$197.87M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RNAC

Cartesian Therapeutics, Inc.

vs ZNTL

Market Cap

$198.33M

PE Ratio

N/A

TTM Avg

5.74

3Y Avg

5.74

5Y Avg

5.74

CNTN

Canton Strategic Holdings Inc

vs ZNTL

Market Cap

$180.47M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs ZNTL

Market Cap

$179.75M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs ZNTL

Market Cap

$179.26M

PE Ratio

1.07

TTM Avg

2.35

3Y Avg

8.36

5Y Avg

8.36

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Zentalis Pharmaceuticals, Inc. (ZNTL)	$190.07M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$189.11M	N/A	N/A	N/A	N/A
RxSight, Inc. (RXST)vs ›	$192.49M	N/A	N/A	N/A	N/A
Surrozen, Inc. (SRZN)vs ›	$197.18M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$182.60M	N/A	N/A	N/A	N/A
Exagen Inc. (XGN)vs ›	$197.87M	N/A	N/A	N/A	N/A
Cartesian Therapeutics, Inc. (RNAC)vs ›	$198.33M	N/A	5.74	5.74	5.74
Canton Strategic Holdings Inc (CNTN)vs ›	$180.47M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$179.75M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$179.26M	1.07	2.35	8.36	8.36

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.67

Forward EPS (Est.)

$-2.08

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ZNTL PE Ratio Metrics

ZNTL Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics